In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
|Articles|January 10, 2020
ideaPoint Partners with SAS
Advertisement
Anaqua’s ideaPoint, a provider of innovation management solutions, has announced a partnership with SAS. The partnership will provide to pharmaceutical companies and academic researchers a clinical trial data sharing solution, with universal guest access to receive and combine data sets from a variety of platforms or individual companies.
Benefiting from this partnership, pharmaceutical companies, academic researchers, and statisticians can search thousands of available clinical studies and submit research proposals through ClinicalStudyDataRequest.com (CSDR), a consortium of 18 clinical study sponsors and funders. As the only platform with global access to a full suite of SAS Analytics programs, it will significantly improve the end-to-end research experience by providing a complete data analysis platform with the most comprehensive set of analytics tools available. The one-stop-shop also offers ideaPoint software to evaluate and track all proposals, questions, and enquiries, and tools to report on metrics.
“Prior to this solution, data scientists were conducting research projects with clinical study data from a myriad of companies offering access to their data on different platforms,” said Scott Shaunessy, CEO of ideaPoint. “The researcher would have to make separate requests on each platform, conduct parallel research projects on each of them, and then try to consolidate the results, without being able to combine all of the data sets. With our new clinical trial data sharing solution, we’ve now solved this problem by allowing researchers to bring all of the data sets into one analysis platform. This offering will support better research outcomes and the advancement of human health.”
“SAS is committed to provide pharmaceutical sponsors a modern data transparency environment where academic researchers have the AI and analytics they need to generate new insights from individual patient-level data from completed clinical trials,” said Mark Lambrecht, Director of the Global Health and Life Sciences Practice at SAS. “With this collaboration, we are convinced that we strike the right balance of securing the patient’s right for privacy, anonymization and consent requirements, while allowing external researchers end-to-end capabilities to search and generate new clinical insights in a sustainable data analytics repository.”
As the first solution providers to enter the clinical trial data sharing space in 2013, ideaPoint and SAS continue to build on their innovative market leader legacy with CSDR. The clinical study data sharing platform consists of 18 sponsors including the most recent partnering of four major academic funders: The Bill & Melinda Gates Foundation, Cancer Research UK, Medical Research Council and Wellcome Trust. The statistical technology and tools offered in this environment are a broad set of open source, proprietary and SAS analytical technologies that serve all the needs at no cost to academic and clinical researchers.
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Where AI Governance in Clinical Development Falls Short
4
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
5